Ocriplasmin (Jetrea®) approved in US for the treatment of symptomatic vitreomacular adhesion

Source: PharmaLive
Area: News
The FDA has approved ocriplasmin (Jetrea®) in the US for the treatment of symptomatic vitreomacular adhesion, a progressive sight threatening condition, making it the first pharmacological agent to be approved for this indication. The drug is administered by intravitreal injection. The approval was based on data from ThromboGenics' Phase III program where ocriplasmin was shown to be superior to placebo (26.5% vs. 10.1%; p<0.01).

Full Story →